MA40480B1 - Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie - Google Patents
Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénieInfo
- Publication number
- MA40480B1 MA40480B1 MA40480A MA40480A MA40480B1 MA 40480 B1 MA40480 B1 MA 40480B1 MA 40480 A MA40480 A MA 40480A MA 40480 A MA40480 A MA 40480A MA 40480 B1 MA40480 B1 MA 40480B1
- Authority
- MA
- Morocco
- Prior art keywords
- schizophrenia
- sustained
- crystallization
- treatment
- release formulations
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- DDINXHAORAAYAD-UHFFFAOYSA-N aripiprazole lauroxil Chemical compound C1=C2N(COC(=O)CCCCCCCCCCC)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl DDINXHAORAAYAD-UHFFFAOYSA-N 0.000 abstract 3
- 229960003798 aripiprazole lauroxil Drugs 0.000 abstract 3
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
La présente invention concerne des procédés de production d'injection retard d'aripiprazole lauroxil recristallisé dans lesquels des particules de l'aripiprazole lauroxil ont une surface d'environ 0,50 à environ 3,3 m²/g; et des cristaux d'aripiprazole lauroxil produits par de tels procédés. La présente invention concerne un procédé de fabrication d'un composé de formule (a) sous forme cristalline dans lequel ra est ch20c(o)r et dans lequel r1 est un fragment aliphatique substitué ou non substitué.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 | |
| PCT/US2015/046525 WO2016032950A1 (fr) | 2014-08-25 | 2015-08-24 | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40480B1 true MA40480B1 (fr) | 2021-08-31 |
Family
ID=55347322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055917A MA55917A (fr) | 2014-08-25 | 2015-08-24 | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
| MA40480A MA40480B1 (fr) | 2014-08-25 | 2015-08-24 | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055917A MA55917A (fr) | 2014-08-25 | 2015-08-24 | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (fr) |
| EP (2) | EP3185867B1 (fr) |
| JP (2) | JP6591546B2 (fr) |
| CN (2) | CN111454207B (fr) |
| AU (2) | AU2015306910B2 (fr) |
| CA (1) | CA2959329C (fr) |
| CY (1) | CY1124058T1 (fr) |
| DK (1) | DK3185867T3 (fr) |
| ES (2) | ES2994850T3 (fr) |
| HR (1) | HRP20210551T1 (fr) |
| HU (1) | HUE054641T2 (fr) |
| IL (1) | IL250661B (fr) |
| LT (1) | LT3185867T (fr) |
| MA (2) | MA55917A (fr) |
| PL (1) | PL3185867T3 (fr) |
| PT (1) | PT3185867T (fr) |
| RS (1) | RS61709B1 (fr) |
| SI (1) | SI3185867T1 (fr) |
| SM (1) | SMT202100212T1 (fr) |
| WO (1) | WO2016032950A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| SMT202100481T1 (it) | 2014-08-18 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni per profarmaci di aripiprazolo |
| SMT202100212T1 (it) * | 2014-08-25 | 2021-07-12 | Alkermes Pharma Ireland Ltd | Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia |
| WO2016181406A1 (fr) * | 2015-05-08 | 2016-11-17 | Davuluri Ramamohan Rao | Procédé amélioré pour la préparation d'aripiprazole doté d'une taille de particule réduite |
| WO2018104953A1 (fr) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Procédé amélioré pour la préparation de 7-{4-[4-(2,3-dichlorophényl)-pipérazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)méthyl dodécanoate |
| ES2903278T3 (es) | 2017-07-28 | 2022-03-31 | Interquim Sa | Procedimiento para la preparación de aripiprazol lauroxil |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| CA2655335C (fr) | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Posologie associee aux esters de paliperidone injectables a action prolongee |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| PT2445502T (pt) | 2009-06-25 | 2017-09-22 | Alkermes Pharma Ireland Ltd | Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos |
| WO2012077134A1 (fr) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Méthode de préparation de polymorphes d'aripiprazole |
| AU2012204174B2 (en) * | 2011-01-07 | 2016-07-21 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
| ES2972387T3 (es) | 2011-03-18 | 2024-06-12 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de sorbitán |
| CA2867121C (fr) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Compositions pharmaceutiques comprenant des esters d'acides gras |
| JP6654042B2 (ja) * | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| SMT202100212T1 (it) * | 2014-08-25 | 2021-07-12 | Alkermes Pharma Ireland Ltd | Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia |
-
2015
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/fr not_active Ceased
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/fr active Active
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 CA CA2959329A patent/CA2959329C/fr active Active
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/fr active Active
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| MX2017011951A (es) | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| EP3865461A4 (fr) | Procédé de traitement des eaux usées de production provenant de la préparation d'oxyde de propylène par procédé de co-oxydation | |
| JP2020511461A5 (fr) | ||
| MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
| MX374296B (es) | Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas | |
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| MA48798B1 (fr) | Procédé de production d'ozanimod | |
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| CU20210007A7 (es) | Derivados de aril-n-arilo para el tratamiento de una infección por virus de ácido ribonucleico (arn) | |
| BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
| MX2021000089A (es) | Derivados de fenil-n-quinolina para el tratamiento de una infeccion por virus de acido ribonucleico (arn). | |
| JP2016529315A5 (fr) | ||
| MA39205A1 (fr) | Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre | |
| EP3792269A4 (fr) | Procédé de production de composé d'acide oligonucléique | |
| MX2019008116A (es) | Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos. | |
| EA202192760A1 (ru) | Трициклические соединения | |
| JP2019523279A5 (fr) | ||
| PH12021551495A1 (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| EA201891095A1 (ru) | Альфа-сложные аминоэфиры производного гидроксипропилтиазолидин карбоксамида и его солевая форма, кристаллический полиморф | |
| RU2007136782A (ru) | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины |